These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 11921158)

  • 1. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
    Bullock R; Connolly C
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
    [No Abstract]   [Full Text] [Related]  

  • 2. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.
    Blesa R
    Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S9-16. PubMed ID: 15249843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
    Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG
    Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma JC
    Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
    [No Abstract]   [Full Text] [Related]  

  • 8. Maintaining functional and behavioral abilities in Alzheimer disease.
    Winblad B
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S34-40. PubMed ID: 11669508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Featured CME topic: dementia. Medication update.
    Slagle MA
    South Med J; 2001 Jul; 94(7):678-81. PubMed ID: 11531174
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacologic management of Alzheimer disease.
    Downey D
    J Neurosci Nurs; 2008 Feb; 40(1):55-9. PubMed ID: 18330411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    McRae TD; Schwam EM
    Curr Med Res Opin; 2002; 18(6):i-iii; author reply iv-vi. PubMed ID: 12442885
    [No Abstract]   [Full Text] [Related]  

  • 12. A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
    Alisky JM
    J Alzheimers Dis; 2003 Dec; 5(6):477-8. PubMed ID: 14757938
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
    van Dyck CH
    CNS Spectr; 2004 Jul; 9(7 Suppl 5):24-8. PubMed ID: 15241297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
    Auriacombe S; Pere JJ;
    Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442
    [No Abstract]   [Full Text] [Related]  

  • 15. [Medical treatment of Alzheimer's disease].
    Johannsen P
    Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
    Schreiter Gasser U; Gasser T
    Fortschr Med Orig; 2001 Nov; 119(3-4):135-8. PubMed ID: 11789125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of donepezil and rivastigmine.
    Grossberg G
    Int J Clin Pract; 2003; 57(1):70-1; author reply 71. PubMed ID: 12587950
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
    Ritchie CW; Ames D; Clayton T; Lai R
    Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Do medicines with aim to anti-Alzheimer favor the arisen of epileptic crisis? Discussion about 3 clinical cases].
    Roy M; Castro-Lionard K; Crawford-Achour E; Desseigne N; Beyens MN; Guy C; Imler D; Cornillon D
    Therapie; 2011; 66(3):291-3. PubMed ID: 23189344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.